for Health Care Providers
Classification of Direct-Acting Antiviral Agents in HCV Treatment Regimens - Hepatitis C
There are 3 targets on the hepatitis C virus (HCV) that currently recommended direct-acting antiviral (DAA) medications attack to destroy the virus. Each DAA medication attacks one of these targets; combination DAA tablets attack more than one target. DAA medications are classified based on which mechanism they use against HCV. Recognizing the DAA medication class(es) becomes particularly important when retreating a patient for HCV who has been previously treated with a DAA-based therapy. There are 3 classes of currently recommended DAA medications:
- NS3/4A protease inhibitors
- NS5A polymerase inhibitors
- NS5B polymerase inhibitors
For details on choosing treatment regimens for individual patients, see the Veterans Health Administration Chronic HCV Infection Treatment Considerations.
| DAA Trade Name | DAA Generic Name | Abbreviation |
|---|---|---|
| Harvoni® | ledipasvir/sofosbuvir | LDV/SOF |
| Zepatier® | elbasvir/grazoprevir | EBR/GZR |
| Epclusa® | sofosbuvir/velpatasvir | SOF/VEL |
| Vosevi® | sofosbuvir/velpatasvir/voxilaprevir | SOF/VEL/VOX |
| Mavyret® | glecaprevir/pibrentasvir | GLE/PIB |
